Compare XRX & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRX | OABI |
|---|---|---|
| Founded | 1906 | 2012 |
| Country | United States | United States |
| Employees | N/A | 114 |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.6M | 253.4M |
| IPO Year | 2019 | N/A |
| Metric | XRX | OABI |
|---|---|---|
| Price | $1.76 | $1.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $6.67 |
| AVG Volume (30 Days) | ★ 3.4M | 281.4K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $117,000,000.00 | N/A |
| Revenue This Year | $8.96 | $74.84 |
| Revenue Next Year | N/A | $40.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $1.22 |
| 52 Week High | $6.80 | $3.33 |
| Indicator | XRX | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 58.72 |
| Support Level | N/A | $1.85 |
| Resistance Level | $2.85 | $2.15 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 40.35 | 70.51 |
Xerox Holdings Corp is an original equipment manufacturing and software company. Xerox operates in one segment--design, development, and sale of printing technology and related solutions--while deriving 60% of its revenue from the U.S. and 40% from international markets. The company is an OEM of multifunction printers, or MFPs (printers that can print, copy, and scan), focusing on large enterprise markets. Apart from equipment, the company provides post-sales services like managed print services help to bring smart servicing and efficiencies to how employers use their print/copy equipment. Xerox is attempting to enter new markets like digital print packaging solutions and printed electronics.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.